This site is for U.S. healthcare professionals only

Prescribing InformationREMS ProgramPatient Site
Request a Rep

Patient Support Program

Support and savings for patients starting on MYQORZO™

MYQORZO & You offers personalized patient support from the day you prescribe MYQORZO and throughout your patients' treatment journey

MYQORZO & You™ logo

Computer Icon

Complete the Start Form to enroll your patient in support

A dedicated MYQORZO Navigator is available to support all enrolled patients within your practice

A MYQORZO Navigator will welcome your patients into the program within 1 business day of enrollment and will:

Copay Icon

Explain savings and support options

Telephone operator icon

Educate and assist with REMS

Copay Icon

Help coordinate shipment of MYQORZO

Copay Icon

Provide ongoing lifestyle support and refill reminders while on MYQORZO

They can also assist with MYQORZO & You enrollment, prior authorization and appeals, and specialty pharmacy coordination

To learn more or get assistance from a MYQORZO Navigator, call 833-MYQORZO or (833-697-6796)

Monday through Friday,
8 AM to 8 PM ET

Woman with headset

Personalized patient support

Support to get eligible patients started

MYQORZO & You Free Trial Offer

Eligible patients with government insurance may start on a one-time, 30-day supply of MYQORZO at no cost while their insurance is being verified.*

Dosing calendar icon

MYQORZO & You Bridge Program

Eligible patients with commercial insurance may receive up to 12 months of MYQORZO at no cost should they face an initial insurance denial.*

Savings to help patients stay on treatment

MYQORZO & You Copay Savings Program

Eligible patients with commercial insurance may pay as little as $5 for MYQORZO.*

MYQORZO & You Echocardiogram Copay Savings Program

Eligible patients with commercial insurance may pay as little as $0 for their echocardiograms.*

Copay savings cardCopay savings card
Copay Icon

Eligible patients can sign up for copay savings

Enroll onlineEnroll Icon

*See Terms and Conditions.

Choose one of 3 ways to enroll

Fax to MYQORZO & You

Checklist Icon

Fax Start Form to 833-697-6799

CoverMyMeds users may also link to the Start Form directly from CoverMyMeds MYQORZO page

Download Start FormDownload Icon

Enroll online

Checklist Icon

Online Enrollment

Enroll online via the portal

Direct to Specialty Pharmacy

Checklist Icon

Fax to Orsini
847-892-1127
or CareMed
877-542-2731

Patients may request ongoing support from a MYQORZO Navigator when the office prescribes directly to a REMS-certified pharmacy

Please direct them to

Tools and resources for HCPs, office staff, and patients

Review the resources

Learn more about treating your patients with MYQORZO

Starting and staying on treatment

REMS=Risk Evaluation and Mitigation Strategy.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.

Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.

CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNING AND PRECAUTIONS

Heart Failure
MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.

Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF <55% is not recommended.

MYQORZO REMS Program

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.

Notable requirements of the MYQORZO REMS Program include:

  • Prescribers must be certified by enrolling in the MYQORZO REMS Program
  • Patients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirements
  • Pharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZO
  • Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.

Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness
MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.

Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.

ADVERSE REACTIONS

Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

INDICATIONS AND USAGE

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Please see full Prescribing Information, including Boxed WARNING.